Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- US FDA Advisory Committee Backs Approval of Edoxaban: Daiichi Sankyo
November 6, 2014
- Kyowa Kirin Completes Construction of New Product Manufacturing Facility at Takasaki Plant
November 5, 2014
- Daiichi Sankyo Posts 30.6% Rise in First-Half Operating Profit, 1.7% in Revenue
November 4, 2014
- Sumitomo Dainippon Will Stick to FY2017 Earnings Targets despite BBI608 Setback: Pres.
November 4, 2014
- Astellas’s First-Half Sales Rise 9.3%, Operating Profit 61.8%
November 4, 2014
- Fujifilm to Take Majority Stake in Regenerative Medicine Startup J-TEC
November 4, 2014
- Bayer Seeks New Indications for Antibiotic Ciproxan
November 4, 2014
- AnGes MG to Initiate Multinational PIII Study of Collategene in Europe
November 4, 2014
- Takeda Aims for Consecutive Sales Growth through FY2022
October 31, 2014
- Sumitomo Dainippon’s Sales Down 1.7% on Drug Price Cuts in Japan
October 31, 2014
- Eisai Flounders in Japan, US Markets, Half-Year Profits Dive 60%
October 31, 2014
- Takeda Reports 2.8% Rise in First-Half Sales
October 31, 2014
- MTPC Files Remicade for Behcet’s Disease with Special Lesions
October 31, 2014
- Smaller Crestor Royalties Send Shionogi’s April-Sept. Sales Lower
October 30, 2014
- MTPC’s Half-Year Sales Dip, but Operating Profit Jumps on Gilenya Royalties
October 30, 2014
- Chugai to Supply Tamiflu for 7 Million Persons This Flu Season
October 30, 2014
- GPCR Consortium, an International Partnership of Industry and Academia, Established: Ono
October 30, 2014
- Safety of Lorcaserin Confirmed in Concomitant Administration with Phentermine: Eisai
October 30, 2014
- Fujifilm to Buy US Vaccine CMO
October 29, 2014
- Mario Stein Named as New President of J&J Consumer Company
October 29, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…